Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
Briakinumab showed no clear difference in failure to maintain clinical response compared with placebo (low certainty).
Briakinumab showed no clear difference in failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) compared with placebo (low certainty).
Briakinumab may leads to lower failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point… compared with placebo (low certainty).
Briakinumab probably leads to lower failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100… compared with placebo (moderate certainty).
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
Briakinumab showed no clear difference in withdrawals due to adverse event** (Pannaccione 2010) compared with placebo (low certainty).